In a phase II trial of 41 patients with resectable head and neck squamous cell carcinoma, neoadjuvant camrelizumab plus apatinib gave a 29.3% major pathologic response rate. Two cycles vs one: 40% vs 23.1% (P=0.300, non-significant). Grade ≥3 toxicity occurred in 2.4%.
RCTn = 41
Jie et al. A Phase II Trial of Chemotherapy-Free Neoadjuvant Camrelizumab plus Apatinib for Resectable HNSCC: Pathologic Response and Vascular-Immune Cross-talk